Global RNA Interference (RNAi) Drug Delivery Market Insights and Forecast to 2026

1.1 RNA Interference (RNAi) Drug Delivery Product Introduction

1.2 Key Market Segments in This Study

1.3 Key Manufacturers Covered: Ranking of Global Top RNA Interference (RNAi) Drug Delivery Manufacturers by Revenue in 2019

1.4 Market by Type

1.4.1 Global RNA Interference (RNAi) Drug Delivery Market Size Growth Rate by Type

1.4.2 Nanoparticle Drug Delivery Technology

1.4.3 Pulmonary Drug Delivery Technology

1.4.4 Nucleic Acid Drug Delivery Technology

1.4.5 Aptamer Drug Delivery Technology

1.5 Market by Application

1.5.1 Global RNA Interference (RNAi) Drug Delivery Market Size Growth Rate by Application

1.5.2 Infectious Diseases

1.5.3 Cardiology

1.5.4 Oncology

1.5.5 Neurology

1.5.6 Ophthalmology

1.5.7 Metabolic Disorders

1.6 Study Objectives

1.7 Years Considered

2 Executive Summary

2.1 Global RNA Interference (RNAi) Drug Delivery Market Size, Estimates and Forecasts

2.1.1 Global RNA Interference (RNAi) Drug Delivery Revenue Estimates and Forecasts 2015-2026

2.1.2 Global RNA Interference (RNAi) Drug Delivery Production Capacity Estimates and Forecasts 2015-2026

2.1.3 Global RNA Interference (RNAi) Drug Delivery Production Estimates and Forecasts 2015-2026

2.2 Global RNA Interference (RNAi) Drug Delivery, Market Size by Producing Regions: 2015 VS 2020 VS 2026

2.3 Analysis of Competitive Landscape

2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

2.3.2 Global RNA Interference (RNAi) Drug Delivery Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.3.3 Global RNA Interference (RNAi) Drug Delivery Manufacturers Geographical Distribution

2.4 Key Trends for RNA Interference (RNAi) Drug Delivery Markets & Products

2.5 Primary Interviews with Key RNA Interference (RNAi) Drug Delivery Players (Opinion Leaders)

3 Market Size by Manufacturers

3.1 Global Top RNA Interference (RNAi) Drug Delivery Manufacturers by Production Capacity

3.1.1 Global Top RNA Interference (RNAi) Drug Delivery Manufacturers by Production Capacity (2015-2020)

3.1.2 Global Top RNA Interference (RNAi) Drug Delivery Manufacturers by Production (2015-2020)

3.1.3 Global Top RNA Interference (RNAi) Drug Delivery Manufacturers Market Share by Production

3.2 Global Top RNA Interference (RNAi) Drug Delivery Manufacturers by Revenue

3.2.1 Global Top RNA Interference (RNAi) Drug Delivery Manufacturers by Revenue (2015-2020)

3.2.2 Global Top RNA Interference (RNAi) Drug Delivery Manufacturers Market Share by Revenue (2015-2020)

3.2.3 Global Top 10 and Top 5 Companies by RNA Interference (RNAi) Drug Delivery Revenue in 2019

3.3 Global RNA Interference (RNAi) Drug Delivery Price by Manufacturers

3.4 Mergers & Acquisitions, Expansion Plans

4 RNA Interference (RNAi) Drug Delivery Production by Regions

4.1 Global RNA Interference (RNAi) Drug Delivery Historic Market Facts & Figures by Regions

4.1.1 Global Top RNA Interference (RNAi) Drug Delivery Regions by Production (2015-2020)

4.1.2 Global Top RNA Interference (RNAi) Drug Delivery Regions by Revenue (2015-2020)

4.2 North America

4.2.1 North America RNA Interference (RNAi) Drug Delivery Production (2015-2020)

4.2.2 North America RNA Interference (RNAi) Drug Delivery Revenue (2015-2020)

4.2.3 Key Players in North America

4.2.4 North America RNA Interference (RNAi) Drug Delivery Import & Export (2015-2020)

4.3 Europe

4.3.1 Europe RNA Interference (RNAi) Drug Delivery Production (2015-2020)

4.3.2 Europe RNA Interference (RNAi) Drug Delivery Revenue (2015-2020)

4.3.3 Key Players in Europe

4.3.4 Europe RNA Interference (RNAi) Drug Delivery Import & Export (2015-2020)

4.4 China

4.4.1 China RNA Interference (RNAi) Drug Delivery Production (2015-2020)

4.4.2 China RNA Interference (RNAi) Drug Delivery Revenue (2015-2020)

4.4.3 Key Players in China

4.4.4 China RNA Interference (RNAi) Drug Delivery Import & Export (2015-2020)

4.5 Japan

4.5.1 Japan RNA Interference (RNAi) Drug Delivery Production (2015-2020)

4.5.2 Japan RNA Interference (RNAi) Drug Delivery Revenue (2015-2020)

4.5.3 Key Players in Japan

4.5.4 Japan RNA Interference (RNAi) Drug Delivery Import & Export (2015-2020)

5 RNA Interference (RNAi) Drug Delivery Consumption by Region

5.1 Global Top RNA Interference (RNAi) Drug Delivery Regions by Consumption

5.1.1 Global Top RNA Interference (RNAi) Drug Delivery Regions by Consumption (2015-2020)

5.1.2 Global Top RNA Interference (RNAi) Drug Delivery Regions Market Share by Consumption (2015-2020)

5.2 North America

5.2.1 North America RNA Interference (RNAi) Drug Delivery Consumption by Application

5.2.2 North America RNA Interference (RNAi) Drug Delivery Consumption by Countries

5.2.3 U.S.

5.2.4 Canada

5.3 Europe

5.3.1 Europe RNA Interference (RNAi) Drug Delivery Consumption by Application

5.3.2 Europe RNA Interference (RNAi) Drug Delivery Consumption by Countries

5.3.3 Germany

5.3.4 France

5.3.5 U.K.

5.3.6 Italy

5.3.7 Russia

5.4 Asia Pacific

5.4.1 Asia Pacific RNA Interference (RNAi) Drug Delivery Consumption by Application

5.4.2 Asia Pacific RNA Interference (RNAi) Drug Delivery Consumption by Regions

5.4.3 China

5.4.4 Japan

5.4.5 South Korea

5.4.6 India

5.4.7 Australia

5.4.8 Taiwan

5.4.9 Indonesia

5.4.10 Thailand

5.4.11 Malaysia

5.4.12 Philippines

5.4.13 Vietnam

5.5 Central & South America

5.5.1 Central & South America RNA Interference (RNAi) Drug Delivery Consumption by Application

5.5.2 Central & South America RNA Interference (RNAi) Drug Delivery Consumption by Country

5.5.3 Mexico

5.5.3 Brazil

5.5.3 Argentina

5.6 Middle East and Africa

5.6.1 Middle East and Africa RNA Interference (RNAi) Drug Delivery Consumption by Application

5.6.2 Middle East and Africa RNA Interference (RNAi) Drug Delivery Consumption by Countries

5.6.3 Turkey

5.6.4 Saudi Arabia

5.6.5 U.A.E

6 Market Size by Type (2015-2026)

6.1 Global RNA Interference (RNAi) Drug Delivery Market Size by Type (2015-2020)

6.1.1 Global RNA Interference (RNAi) Drug Delivery Production by Type (2015-2020)

6.1.2 Global RNA Interference (RNAi) Drug Delivery Revenue by Type (2015-2020)

6.1.3 RNA Interference (RNAi) Drug Delivery Price by Type (2015-2020)

6.2 Global RNA Interference (RNAi) Drug Delivery Market Forecast by Type (2021-2026)

6.2.1 Global RNA Interference (RNAi) Drug Delivery Production Forecast by Type (2021-2026)

6.2.2 Global RNA Interference (RNAi) Drug Delivery Revenue Forecast by Type (2021-2026)

6.2.3 Global RNA Interference (RNAi) Drug Delivery Price Forecast by Type (2021-2026)

6.3 Global RNA Interference (RNAi) Drug Delivery Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

7 Market Size by Application (2015-2026)

7.2.1 Global RNA Interference (RNAi) Drug Delivery Consumption Historic Breakdown by Application (2015-2020)

7.2.2 Global RNA Interference (RNAi) Drug Delivery Consumption Forecast by Application (2021-2026)

8 Corporate Profiles

8.1 Metabolic disorders

8.1.1 Metabolic disorders Corporation Information

8.1.2 Metabolic disorders Overview

8.1.3 Metabolic disorders Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)

8.1.4 Metabolic disorders Product Description

8.1.5 Metabolic disorders Related Developments

8.2 Alnylam Pharmaceuticals Inc

8.2.1 Alnylam Pharmaceuticals Inc Corporation Information

8.2.2 Alnylam Pharmaceuticals Inc Overview

8.2.3 Alnylam Pharmaceuticals Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)

8.2.4 Alnylam Pharmaceuticals Inc Product Description

8.2.5 Alnylam Pharmaceuticals Inc Related Developments

8.3 Merck & Co. Inc

8.3.1 Merck & Co. Inc Corporation Information

8.3.2 Merck & Co. Inc Overview

8.3.3 Merck & Co. Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)

8.3.4 Merck & Co. Inc Product Description

8.3.5 Merck & Co. Inc Related Developments

8.4 Access Pharmaceuticals Inc

8.4.1 Access Pharmaceuticals Inc Corporation Information

8.4.2 Access Pharmaceuticals Inc Overview

8.4.3 Access Pharmaceuticals Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)

8.4.4 Access Pharmaceuticals Inc Product Description

8.4.5 Access Pharmaceuticals Inc Related Developments

8.5 Dicerna Pharmaceuticals Inc

8.5.1 Dicerna Pharmaceuticals Inc Corporation Information

8.5.2 Dicerna Pharmaceuticals Inc Overview

8.5.3 Dicerna Pharmaceuticals Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)

8.5.4 Dicerna Pharmaceuticals Inc Product Description

8.5.5 Dicerna Pharmaceuticals Inc Related Developments

8.6 Calondo Pharmaceuticals Inc

8.6.1 Calondo Pharmaceuticals Inc Corporation Information

8.6.2 Calondo Pharmaceuticals Inc Overview

8.6.3 Calondo Pharmaceuticals Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)

8.6.4 Calondo Pharmaceuticals Inc Product Description

8.6.5 Calondo Pharmaceuticals Inc Related Developments

8.7 Marina Biotech Inc

8.7.1 Marina Biotech Inc Corporation Information

8.7.2 Marina Biotech Inc Overview

8.7.3 Marina Biotech Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)

8.7.4 Marina Biotech Inc Product Description

8.7.5 Marina Biotech Inc Related Developments

8.8 RXi Pharmaceuticals Corp

8.8.1 RXi Pharmaceuticals Corp Corporation Information

8.8.2 RXi Pharmaceuticals Corp Overview

8.8.3 RXi Pharmaceuticals Corp Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)

8.8.4 RXi Pharmaceuticals Corp Product Description

8.8.5 RXi Pharmaceuticals Corp Related Developments

8.9 Quark Pharmaceuticals Inc

8.9.1 Quark Pharmaceuticals Inc Corporation Information

8.9.2 Quark Pharmaceuticals Inc Overview

8.9.3 Quark Pharmaceuticals Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)

8.9.4 Quark Pharmaceuticals Inc Product Description

8.9.5 Quark Pharmaceuticals Inc Related Developments

8.10 Silence Therapeutics plc

8.10.1 Silence Therapeutics plc Corporation Information

8.10.2 Silence Therapeutics plc Overview

8.10.3 Silence Therapeutics plc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)

8.10.4 Silence Therapeutics plc Product Description

8.10.5 Silence Therapeutics plc Related Developments

8.11 Tacere Therapeutics Inc

8.11.1 Tacere Therapeutics Inc Corporation Information

8.11.2 Tacere Therapeutics Inc Overview

8.11.3 Tacere Therapeutics Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)

8.11.4 Tacere Therapeutics Inc Product Description

8.11.5 Tacere Therapeutics Inc Related Developments

8.12 PhaseRx Inc

8.12.1 PhaseRx Inc Corporation Information

8.12.2 PhaseRx Inc Overview

8.12.3 PhaseRx Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)

8.12.4 PhaseRx Inc Product Description

8.12.5 PhaseRx Inc Related Developments

8.13 Sirnaomics Inc

8.13.1 Sirnaomics Inc Corporation Information

8.13.2 Sirnaomics Inc Overview

8.13.3 Sirnaomics Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)

8.13.4 Sirnaomics Inc Product Description

8.13.5 Sirnaomics Inc Related Developments

8.14 Traversa Therapeutics Inc

8.14.1 Traversa Therapeutics Inc Corporation Information

8.14.2 Traversa Therapeutics Inc Overview

8.14.3 Traversa Therapeutics Inc Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)

8.14.4 Traversa Therapeutics Inc Product Description

8.14.5 Traversa Therapeutics Inc Related Developments

9 RNA Interference (RNAi) Drug Delivery Production Forecast by Regions

9.1 Global Top RNA Interference (RNAi) Drug Delivery Regions Forecast by Revenue (2021-2026)

9.2 Global Top RNA Interference (RNAi) Drug Delivery Regions Forecast by Production (2021-2026)

9.3 Key RNA Interference (RNAi) Drug Delivery Production Regions Forecast

9.3.1 North America

9.3.2 Europe

9.3.3 China

9.3.4 Japan

10 RNA Interference (RNAi) Drug Delivery Consumption Forecast by Region

10.1 Global RNA Interference (RNAi) Drug Delivery Consumption Forecast by Region (2021-2026)

10.2 North America RNA Interference (RNAi) Drug Delivery Consumption Forecast by Region (2021-2026)

10.3 Europe RNA Interference (RNAi) Drug Delivery Consumption Forecast by Region (2021-2026)

10.4 Asia Pacific RNA Interference (RNAi) Drug Delivery Consumption Forecast by Region (2021-2026)

10.5 Latin America RNA Interference (RNAi) Drug Delivery Consumption Forecast by Region (2021-2026)

10.6 Middle East and Africa RNA Interference (RNAi) Drug Delivery Consumption Forecast by Region (2021-2026)

11 Value Chain and Sales Channels Analysis

11.1 Value Chain Analysis

11.2 Sales Channels Analysis

11.2.1 RNA Interference (RNAi) Drug Delivery Sales Channels

11.2.2 RNA Interference (RNAi) Drug Delivery Distributors

11.3 RNA Interference (RNAi) Drug Delivery Customers

12 Market Opportunities & Challenges, Risks and Influences Factors Analysis

12.1 RNA Interference (RNAi) Drug Delivery Industry

12.2 Market Trends

12.3 Market Opportunities and Drivers

12.4 Market Challenges

12.5 RNA Interference (RNAi) Drug Delivery Market Risks/Restraints

12.6 Porter's Five Forces Analysis

13 Key Finding in The Global RNA Interference (RNAi) Drug Delivery Study

14 Appendix

14.1 Research Methodology

14.1.1 Methodology/Research Approach

14.1.2 Data Source

14.2 Author Details

14.3 Disclaimer

Table 1. RNA Interference (RNAi) Drug Delivery Key Market Segments in This Study

Table 2. Ranking of Global Top RNA Interference (RNAi) Drug Delivery Manufacturers by Revenue (US$ Million) in 2019

Table 3. Global RNA Interference (RNAi) Drug Delivery Market Size Growth Rate by Type 2020-2026 (K Units) (Million US$)

Table 4. Major Manufacturers of Nanoparticle Drug Delivery Technology

Table 5. Major Manufacturers of Pulmonary Drug Delivery Technology

Table 6. Major Manufacturers of Nucleic Acid Drug Delivery Technology

Table 7. Major Manufacturers of Aptamer Drug Delivery Technology

Table 8. Global RNA Interference (RNAi) Drug Delivery Market Size Growth Rate by Application 2020-2026 (K Units)

Table 9. Global RNA Interference (RNAi) Drug Delivery Market Size by Region in US$ Million: 2015 VS 2020 VS 2026

Table 10. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 11. Global RNA Interference (RNAi) Drug Delivery by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in RNA Interference (RNAi) Drug Delivery as of 2019)

Table 12. RNA Interference (RNAi) Drug Delivery Manufacturing Base Distribution and Headquarters

Table 13. Manufacturers RNA Interference (RNAi) Drug Delivery Product Offered

Table 14. Date of Manufacturers Enter into RNA Interference (RNAi) Drug Delivery Market

Table 15. Key Trends for RNA Interference (RNAi) Drug Delivery Markets & Products

Table 16. Main Points Interviewed from Key RNA Interference (RNAi) Drug Delivery Players

Table 17. Global RNA Interference (RNAi) Drug Delivery Production Capacity by Manufacturers (2015-2020) (K Units)

Table 18. Global RNA Interference (RNAi) Drug Delivery Production Share by Manufacturers (2015-2020)

Table 19. RNA Interference (RNAi) Drug Delivery Revenue by Manufacturers (2015-2020) (Million US$)

Table 20. RNA Interference (RNAi) Drug Delivery Revenue Share by Manufacturers (2015-2020)

Table 21. RNA Interference (RNAi) Drug Delivery Price by Manufacturers 2015-2020 (USD/Unit)

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global RNA Interference (RNAi) Drug Delivery Production by Regions (2015-2020) (K Units)

Table 24. Global RNA Interference (RNAi) Drug Delivery Production Market Share by Regions (2015-2020)

Table 25. Global RNA Interference (RNAi) Drug Delivery Revenue by Regions (2015-2020) (US$ Million)

Table 26. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Regions (2015-2020)

Table 27. Key RNA Interference (RNAi) Drug Delivery Players in North America

Table 28. Import & Export of RNA Interference (RNAi) Drug Delivery in North America (K Units)

Table 29. Key RNA Interference (RNAi) Drug Delivery Players in Europe

Table 30. Import & Export of RNA Interference (RNAi) Drug Delivery in Europe (K Units)

Table 31. Key RNA Interference (RNAi) Drug Delivery Players in China

Table 32. Import & Export of RNA Interference (RNAi) Drug Delivery in China (K Units)

Table 33. Key RNA Interference (RNAi) Drug Delivery Players in Japan

Table 34. Import & Export of RNA Interference (RNAi) Drug Delivery in Japan (K Units)

Table 35. Global RNA Interference (RNAi) Drug Delivery Consumption by Regions (2015-2020) (K Units)

Table 36. Global RNA Interference (RNAi) Drug Delivery Consumption Market Share by Regions (2015-2020)

Table 37. North America RNA Interference (RNAi) Drug Delivery Consumption by Application (2015-2020) (K Units)

Table 38. North America RNA Interference (RNAi) Drug Delivery Consumption by Countries (2015-2020) (K Units)

Table 39. Europe RNA Interference (RNAi) Drug Delivery Consumption by Application (2015-2020) (K Units)

Table 40. Europe RNA Interference (RNAi) Drug Delivery Consumption by Countries (2015-2020) (K Units)

Table 41. Asia Pacific RNA Interference (RNAi) Drug Delivery Consumption by Application (2015-2020) (K Units)

Table 42. Asia Pacific RNA Interference (RNAi) Drug Delivery Consumption Market Share by Application (2015-2020) (K Units)

Table 43. Asia Pacific RNA Interference (RNAi) Drug Delivery Consumption by Regions (2015-2020) (K Units)

Table 44. Latin America RNA Interference (RNAi) Drug Delivery Consumption by Application (2015-2020) (K Units)

Table 45. Latin America RNA Interference (RNAi) Drug Delivery Consumption by Countries (2015-2020) (K Units)

Table 46. Middle East and Africa RNA Interference (RNAi) Drug Delivery Consumption by Application (2015-2020) (K Units)

Table 47. Middle East and Africa RNA Interference (RNAi) Drug Delivery Consumption by Countries (2015-2020) (K Units)

Table 48. Global RNA Interference (RNAi) Drug Delivery Production by Type (2015-2020) (K Units)

Table 49. Global RNA Interference (RNAi) Drug Delivery Production Share by Type (2015-2020)

Table 50. Global RNA Interference (RNAi) Drug Delivery Revenue by Type (2015-2020) (Million US$)

Table 51. Global RNA Interference (RNAi) Drug Delivery Revenue Share by Type (2015-2020)

Table 52. RNA Interference (RNAi) Drug Delivery Price by Type 2015-2020 (USD/Unit)

Table 53. Global RNA Interference (RNAi) Drug Delivery Consumption by Application (2015-2020) (K Units)

Table 54. Global RNA Interference (RNAi) Drug Delivery Consumption Share by Application (2015-2020)

Table 55. Metabolic disorders Corporation Information

Table 56. Metabolic disorders Description and Major Businesses

Table 57. Metabolic disorders RNA Interference (RNAi) Drug Delivery Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 58. Metabolic disorders Product

Table 59. Metabolic disorders Recent Development

Table 60. Alnylam Pharmaceuticals Inc Corporation Information

Table 61. Alnylam Pharmaceuticals Inc Description and Major Businesses

Table 62. Alnylam Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 63. Alnylam Pharmaceuticals Inc Product

Table 64. Alnylam Pharmaceuticals Inc Recent Development

Table 65. Merck & Co. Inc Corporation Information

Table 66. Merck & Co. Inc Description and Major Businesses

Table 67. Merck & Co. Inc RNA Interference (RNAi) Drug Delivery Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 68. Merck & Co. Inc Product

Table 69. Merck & Co. Inc Recent Development

Table 70. Access Pharmaceuticals Inc Corporation Information

Table 71. Access Pharmaceuticals Inc Description and Major Businesses

Table 72. Access Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 73. Access Pharmaceuticals Inc Product

Table 74. Access Pharmaceuticals Inc Recent Development

Table 75. Dicerna Pharmaceuticals Inc Corporation Information

Table 76. Dicerna Pharmaceuticals Inc Description and Major Businesses

Table 77. Dicerna Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 78. Dicerna Pharmaceuticals Inc Product

Table 79. Dicerna Pharmaceuticals Inc Recent Development

Table 80. Calondo Pharmaceuticals Inc Corporation Information

Table 81. Calondo Pharmaceuticals Inc Description and Major Businesses

Table 82. Calondo Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 83. Calondo Pharmaceuticals Inc Product

Table 84. Calondo Pharmaceuticals Inc Recent Development

Table 85. Marina Biotech Inc Corporation Information

Table 86. Marina Biotech Inc Description and Major Businesses

Table 87. Marina Biotech Inc RNA Interference (RNAi) Drug Delivery Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 88. Marina Biotech Inc Product

Table 89. Marina Biotech Inc Recent Development

Table 90. RXi Pharmaceuticals Corp Corporation Information

Table 91. RXi Pharmaceuticals Corp Description and Major Businesses

Table 92. RXi Pharmaceuticals Corp RNA Interference (RNAi) Drug Delivery Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 93. RXi Pharmaceuticals Corp Product

Table 94. RXi Pharmaceuticals Corp Recent Development

Table 95. Quark Pharmaceuticals Inc Corporation Information

Table 96. Quark Pharmaceuticals Inc Description and Major Businesses

Table 97. Quark Pharmaceuticals Inc RNA Interference (RNAi) Drug Delivery Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 98. Quark Pharmaceuticals Inc Product

Table 99. Quark Pharmaceuticals Inc Recent Development

Table 100. Silence Therapeutics plc Corporation Information

Table 101. Silence Therapeutics plc Description and Major Businesses

Table 102. Silence Therapeutics plc RNA Interference (RNAi) Drug Delivery Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 103. Silence Therapeutics plc Product

Table 104. Silence Therapeutics plc Recent Development

Table 105. Tacere Therapeutics Inc Corporation Information

Table 106. Tacere Therapeutics Inc Description and Major Businesses

Table 107. Tacere Therapeutics Inc RNA Interference (RNAi) Drug Delivery Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 108. Tacere Therapeutics Inc Product

Table 109. Tacere Therapeutics Inc Recent Development

Table 110. PhaseRx Inc Corporation Information

Table 111. PhaseRx Inc Description and Major Businesses

Table 112. PhaseRx Inc RNA Interference (RNAi) Drug Delivery Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 113. PhaseRx Inc Product

Table 114. PhaseRx Inc Recent Development

Table 115. Sirnaomics Inc Corporation Information

Table 116. Sirnaomics Inc Description and Major Businesses

Table 117. Sirnaomics Inc RNA Interference (RNAi) Drug Delivery Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 118. Sirnaomics Inc Product

Table 119. Sirnaomics Inc Recent Development

Table 120. Traversa Therapeutics Inc Corporation Information

Table 121. Traversa Therapeutics Inc Description and Major Businesses

Table 122. Traversa Therapeutics Inc RNA Interference (RNAi) Drug Delivery Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)

Table 123. Traversa Therapeutics Inc Product

Table 124. Traversa Therapeutics Inc Recent Development

Table 125. Global RNA Interference (RNAi) Drug Delivery Revenue Forecast by Region (2021-2026) (Million US$)

Table 126. Global RNA Interference (RNAi) Drug Delivery Production Forecast by Regions (2021-2026) (K Units)

Table 127. Global RNA Interference (RNAi) Drug Delivery Production Forecast by Type (2021-2026) (K Units)

Table 128. Global RNA Interference (RNAi) Drug Delivery Revenue Forecast by Type (2021-2026) (Million US$)

Table 129. North America RNA Interference (RNAi) Drug Delivery Consumption Forecast by Regions (2021-2026) (K Units)

Table 130. Europe RNA Interference (RNAi) Drug Delivery Consumption Forecast by Regions (2021-2026) (K Units)

Table 131. Asia Pacific RNA Interference (RNAi) Drug Delivery Consumption Forecast by Regions (2021-2026) (K Units)

Table 132. Latin America RNA Interference (RNAi) Drug Delivery Consumption Forecast by Regions (2021-2026) (K Units)

Table 133. Middle East and Africa RNA Interference (RNAi) Drug Delivery Consumption Forecast by Regions (2021-2026) (K Units)

Table 134. RNA Interference (RNAi) Drug Delivery Distributors List

Table 135. RNA Interference (RNAi) Drug Delivery Customers List

Table 136. Key Opportunities and Drivers: Impact Analysis (2021-2026)

Table 137. Key Challenges

Table 138. Market Risks

Table 139. Research Programs/Design for This Report

Table 140. Key Data Information from Secondary Sources

Table 141. Key Data Information from Primary Sources

List of Fifures

Figure 1. RNA Interference (RNAi) Drug Delivery Product Picture

Figure 2. Global RNA Interference (RNAi) Drug Delivery Production Market Share by Type in 2020 & 2026

Figure 3. Nanoparticle Drug Delivery Technology Product Picture

Figure 4. Pulmonary Drug Delivery Technology Product Picture

Figure 5. Nucleic Acid Drug Delivery Technology Product Picture

Figure 6. Aptamer Drug Delivery Technology Product Picture

Figure 7. Global RNA Interference (RNAi) Drug Delivery Consumption Market Share by Application in 2020 & 2026

Figure 8. Infectious Diseases

Figure 9. Cardiology

Figure 10. Oncology

Figure 11. Neurology

Figure 12. Ophthalmology

Figure 13. Metabolic Disorders

Figure 14. RNA Interference (RNAi) Drug Delivery Report Years Considered

Figure 15. Global RNA Interference (RNAi) Drug Delivery Revenue 2015-2026 (Million US$)

Figure 16. Global RNA Interference (RNAi) Drug Delivery Production Capacity 2015-2026 (K Units)

Figure 17. Global RNA Interference (RNAi) Drug Delivery Production 2015-2026 (K Units)

Figure 18. Global RNA Interference (RNAi) Drug Delivery Market Share Scenario by Region in Percentage: 2020 Versus 2026

Figure 19. RNA Interference (RNAi) Drug Delivery Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019

Figure 20. Global RNA Interference (RNAi) Drug Delivery Production Share by Manufacturers in 2015

Figure 21. The Top 10 and Top 5 Players Market Share by RNA Interference (RNAi) Drug Delivery Revenue in 2019

Figure 22. Global RNA Interference (RNAi) Drug Delivery Production Market Share by Region (2015-2020)

Figure 23. RNA Interference (RNAi) Drug Delivery Production Growth Rate in North America (2015-2020) (K Units)

Figure 24. RNA Interference (RNAi) Drug Delivery Revenue Growth Rate in North America (2015-2020) (US$ Million)

Figure 25. RNA Interference (RNAi) Drug Delivery Production Growth Rate in Europe (2015-2020) (K Units)

Figure 26. RNA Interference (RNAi) Drug Delivery Revenue Growth Rate in Europe (2015-2020) (US$ Million)

Figure 27. RNA Interference (RNAi) Drug Delivery Production Growth Rate in China (2015-2020) (K Units)

Figure 28. RNA Interference (RNAi) Drug Delivery Revenue Growth Rate in China (2015-2020) (US$ Million)

Figure 29. RNA Interference (RNAi) Drug Delivery Production Growth Rate in Japan (2015-2020) (K Units)

Figure 30. RNA Interference (RNAi) Drug Delivery Revenue Growth Rate in Japan (2015-2020) (US$ Million)

Figure 31. Global RNA Interference (RNAi) Drug Delivery Consumption Market Share by Regions 2015-2020

Figure 32. North America RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 33. North America RNA Interference (RNAi) Drug Delivery Consumption Market Share by Application in 2019

Figure 34. North America RNA Interference (RNAi) Drug Delivery Consumption Market Share by Countries in 2019

Figure 35. U.S. RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 36. Canada RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 37. Europe RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 38. Europe RNA Interference (RNAi) Drug Delivery Consumption Market Share by Application in 2019

Figure 39. Europe RNA Interference (RNAi) Drug Delivery Consumption Market Share by Countries in 2019

Figure 40. Germany RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 41. France RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 42. U.K. RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 43. Italy RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 44. Russia RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 45. Asia Pacific RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (K Units)

Figure 46. Asia Pacific RNA Interference (RNAi) Drug Delivery Consumption Market Share by Application in 2019

Figure 47. Asia Pacific RNA Interference (RNAi) Drug Delivery Consumption Market Share by Regions in 2019

Figure 48. China RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 49. Japan RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 50. South Korea RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 51. India RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 52. Australia RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 53. Taiwan RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 54. Indonesia RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 55. Thailand RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 56. Malaysia RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 57. Philippines RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 58. Vietnam RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 59. Latin America RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (K Units)

Figure 60. Latin America RNA Interference (RNAi) Drug Delivery Consumption Market Share by Application in 2019

Figure 61. Latin America RNA Interference (RNAi) Drug Delivery Consumption Market Share by Countries in 2019

Figure 62. Mexico RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 63. Brazil RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 64. Argentina RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 65. Middle East and Africa RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (K Units)

Figure 66. Middle East and Africa RNA Interference (RNAi) Drug Delivery Consumption Market Share by Application in 2019

Figure 67. Middle East and Africa RNA Interference (RNAi) Drug Delivery Consumption Market Share by Countries in 2019

Figure 68. Turkey RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 69. Saudi Arabia RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 70. U.A.E RNA Interference (RNAi) Drug Delivery Consumption and Growth Rate (2015-2020) (K Units)

Figure 71. Global RNA Interference (RNAi) Drug Delivery Production Market Share by Type (2015-2020)

Figure 72. Global RNA Interference (RNAi) Drug Delivery Production Market Share by Type in 2019

Figure 73. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Type (2015-2020)

Figure 74. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share by Type in 2019

Figure 75. Global RNA Interference (RNAi) Drug Delivery Production Market Share Forecast by Type (2021-2026)

Figure 76. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share Forecast by Type (2021-2026)

Figure 77. Global RNA Interference (RNAi) Drug Delivery Market Share by Price Range (2015-2020)

Figure 78. Global RNA Interference (RNAi) Drug Delivery Consumption Market Share by Application (2015-2020)

Figure 79. Global RNA Interference (RNAi) Drug Delivery Value (Consumption) Market Share by Application (2015-2020)

Figure 80. Global RNA Interference (RNAi) Drug Delivery Consumption Market Share Forecast by Application (2021-2026)

Figure 81. Global RNA Interference (RNAi) Drug Delivery Revenue Forecast by Regions (2021-2026) (US$ Million)

Figure 82. Global RNA Interference (RNAi) Drug Delivery Revenue Market Share Forecast by Regions ((2021-2026))

Figure 83. Global RNA Interference (RNAi) Drug Delivery Production Forecast by Regions (2021-2026) (K Units)

Figure 84. North America RNA Interference (RNAi) Drug Delivery Production Forecast (2021-2026) (K Units)

Figure 85. North America RNA Interference (RNAi) Drug Delivery Revenue Forecast (2021-2026) (US$ Million)

Figure 86. Europe RNA Interference (RNAi) Drug Delivery Production Forecast (2021-2026) (K Units)

Figure 87. Europe RNA Interference (RNAi) Drug Delivery Revenue Forecast (2021-2026) (US$ Million)

Figure 88. China RNA Interference (RNAi) Drug Delivery Production Forecast (2021-2026) (K Units)

Figure 89. China RNA Interference (RNAi) Drug Delivery Revenue Forecast (2021-2026) (US$ Million)

Figure 90. Japan RNA Interference (RNAi) Drug Delivery Production Forecast (2021-2026) (K Units)

Figure 91. Japan RNA Interference (RNAi) Drug Delivery Revenue Forecast (2021-2026) (US$ Million)

Figure 92. Global RNA Interference (RNAi) Drug Delivery Consumption Market Share Forecast by Region (2021-2026)

Figure 93. RNA Interference (RNAi) Drug Delivery Value Chain

Figure 94. Channels of Distribution

Figure 95. Distributors Profiles

Figure 96. Porter's Five Forces Analysis

Figure 97. Bottom-up and Top-down Approaches for This Report

Figure 98. Data Triangulation

Figure 99. Key Executives Interviewed